Contact Us

Case Review Form
*    Denotes required field.

Describe accident or indicate name of drug or device

   * First Name 

   * Last Name 

   * Email 

Phone 

   * Please describe your case:

What injury have you suffered?

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Lawsuit Alleges Eliquis Caused Internal Bleeding Blindness

Oct 20, 2016
Lawsuit Alleges Eliquis Caused Internal Bleeding Blindness

A Louisiana man has filed a lawsuit alleging that Eliquis, an anticoagulant developed by Bristol-Myers Squibb and Pfizer, caused internal bleeding and subsequent partial blindness. The lawsuit alleges that the drug makers knew Eliquis presented a risk of uncontrollable bleeding but failed to warn patients or the medical community.

According to the complaint, the plaintiff began taking Eliquis in June 2013 to reduce the risk of blood clot and related injuries, such as heart attack and stroke, associated with atrial fibrillation. Atrial fibrillation is a type of abnormal heart rhythm that increases the risk of blood clots. The plaintiff alleges that neither he nor his physician knew about the risk of irreversible bleeding with Eliquis. He alleges that he took the drug as directed until April 2016.

The plaintiff suffered internal eye bleeding, allegedly due to Eliquis side effects, in August 2015. He alleges that these problems persisted for several months. Although he was able to get treated for the internal bleeding, he is now partially blind in his right eye. The plaintiff alleges that Eliquis side effects continue to cause chronic pain.

Eliquis is part of a new generation of anticoagulants, alongside drugs such as Pradaxa and Xarelto. These medications were released in an effort to compete with warfarin, a decades-old blood thinner. The U.S. Food and Drug Administration (FDA) approved Eliquis in 2012.

Anticoagulants are prescribed to patients who are at risk of a life-threatening blood clot. These medications work by inhibiting the blood's ability to clot, but the caveat is that blood may not clot as easily when necessary, such as when internal bleeding occurs. Plaintiffs in the litigation point out that with warfarin, there is an antidote to reverse the drug's effects if bleeding occurs. However, no such antidote exists for Eliquis. The lawsuits allege that Eliquis makers were aware of this drawback, but failed to warn patients or their physicians.

The plaintiff alleges that he never would have taken Eliquis if drug makers adequately disclosed the risks to him and his physician. His lawsuit seeks damages for multiple counts of negligence and failure to warn.

Parker | Waichman Logo Legal Help for Victims
For a free lawsuit evaluation with an attorney, please fill out our online form, or call 1-800-YOURLAWYER (1-800-968-7529) today. Click Here to be redirected to our home page.

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo